A2 Biotherapeutics Inc.
Privately held: no public share price · United States
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | EGFR (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 1/2 | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung CancerColorectal CancerPancreatic Cancer | |
| Phase 1/2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2028 (1)
Financial reports
No financial reports recorded.